Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Conditions:   HER2-negative Breast Cancer;   Triple Negative Breast Cancer Interventions:   Drug: Capecitabine;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Sacituzumab govitecan Sponsors:   German Breast Group;   Immunomedics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials